Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026
Key facts:
Expanding advanced manufacturing capacity and services: Recent investments in biologics, sterile fill-finish, oral solid dose manufacturing and integrated device assembly strengthen Thermo Fisher’s ability to support customers from development through commercialization.
Advancing clinical development and evidence generation: Thermo Fisher is showcasing expanded clinical research and data intelligence capabilities through Clario, AI-enabled analytics and integrated capabilities designed to help improve trial efficiency and decision-making.
Enhancing AI-enabled research, connected scientific workflows and emerging biotech innovation: New strategic relationships and digital solutions with leaders including NVIDIA, OpenAI, TetraScience and BenchSci — alongside Accelerator™ Drug Development collaborations — help customers automate laboratory workflows, unify scientific data and generate deeper insights across R&D.
